Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis.
SARS-CoV-2 infection
coronavirus disease 2019
vaccine effectiveness
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
21 Jan 2022
21 Jan 2022
Historique:
received:
17
11
2021
revised:
29
12
2021
accepted:
30
12
2021
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
(1) Background: The objective of this study was to assess the effectiveness of SARS-CoV-2 vaccines in terms of prevention of disease and transmission in the pre-Delta era. The evaluation was narrowed to two mRNA vaccines and two modified adenovirus-vectored vaccines. (2) Methods: The overall risk of any SARS-CoV-2 infection confirmed by positive real-time Polymerase Chain Reaction (PCR) test was estimated in partially and fully vaccinated individuals. The evidence synthesis was pursued through a random-effects meta-analysis. The effect size was expressed as relative risk (RR) and RRR (RR reduction) of SARS-CoV-2 infection following vaccination. Heterogeneity was investigated through a between-study heterogeneity analysis and a subgroup meta-analysis. (3) Results: The systematic review identified 27 studies eligible for the quantitative synthesis. Partially vaccinated individuals presented a RRR = 73% (95%CI = 59-83%) for positive SARS-CoV-2 PCR (RR = 0.27) and a RRR=79% (95%CI = 30-93%) for symptomatic SARS-CoV-2 PCR (RR = 0.21). Fully vaccinated individuals showed a RRR = 94% (95%CI = 88-98%) for SARS-CoV-2 positive PCR (RR = 0.06) compared to unvaccinated individuals. The full BNT162b2 vaccination protocol achieved a RRR = 84-94% against any SARS-CoV-2-positive PCR and a RRR = 68-84% against symptomatic positive PCR. (4) Conclusions: The meta-analysis results suggest that full vaccination might block transmission. In particular, the risk of SARS-CoV-2 infection appeared higher for non-B.1.1.7 variants and individuals aged ≥69 years. Considering the high level of heterogeneity, these findings must be taken with caution. Further research on SARS-CoV-2 vaccine effectiveness against emerging SARS-CoV-2 variants is encouraged.
Identifiants
pubmed: 35214615
pii: vaccines10020157
doi: 10.3390/vaccines10020157
pmc: PMC8879968
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Ministry of Health Italy
Références
Open Forum Infect Dis. 2021 Sep 17;8(10):ofab465
pubmed: 34646910
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Rev Esp Salud Publica. 2021 Apr 29;95:
pubmed: 33913444
Clin Infect Dis. 2021 Jul 03;:
pubmed: 34216472
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
Clin Infect Dis. 2022 Jan 7;74(1):59-65
pubmed: 33704435
N Engl J Med. 2021 May 6;384(18):1775-1777
pubmed: 33755373
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):674-679
pubmed: 33956782
BMJ Open. 2020 Aug 16;10(8):e039652
pubmed: 32801208
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Lancet Infect Dis. 2021 Nov;21(11):1529-1538
pubmed: 34174193
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Mil Med Res. 2020 Feb 29;7(1):7
pubmed: 32111253
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 May 20;384(20):1962-1963
pubmed: 33755374
Euro Surveill. 2021 Apr;26(17):
pubmed: 33928898
Res Synth Methods. 2010 Apr;1(2):112-25
pubmed: 26061377
Emerg Infect Dis. 2021 Oct;27(10):2595-2603
pubmed: 34314670
Stat Med. 2002 Sep 30;21(18):2641-52
pubmed: 12228882
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Res Synth Methods. 2012 Sep;3(3):214-23
pubmed: 26062164
BMC Med. 2021 Oct 18;19(1):275
pubmed: 34663326
Elife. 2021 Apr 08;10:
pubmed: 33830018
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379
pubmed: 33900384
JAMA Netw Open. 2021 Nov 1;4(11):e2132540
pubmed: 34726743
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Stat Med. 2004 Jun 15;23(11):1663-82
pubmed: 15160401
Lancet Infect Dis. 2021 Nov;21(11):1539-1548
pubmed: 34174190
MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):396-401
pubmed: 33735160
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Lancet Infect Dis. 2021 Jul;21(7):890-891
pubmed: 33930321
Lancet. 2021 Mar 6;397(10277):875-877
pubmed: 33610193